NPS Pharmaceuticals price target raised to $42 from $35 at Canaccord
Canaccord raised its price target on NPS Pharmaceuticals citing expectations for its sales ramp and its pipeline progress. The firm views the company as a three product play with royalties that will provide a cash base and M&A options. Shares are Buy rated. Flyonthewall
HPV causes the cancers. Stop HPV and you stop the cancer. The antigen produced by hpv-llm comes from hpv. Thus, the immune system will only attack those cancer cells that are hpv infected. I think.
In the case of dog, HER2 is the target that is expressed in llmo, so only cancers over-expressing HER2 will be killed. I am not sure how many human lung cancers over-express HER2, but breast and gastric cancers do.
As to why advaxis has psa targeting, when it is a more unpredictable target than the well studied HER2, I really am not sure why.
Interesting article I stumbled onto. HER2 surface antigen is up-regulated on blasts of approximately one-third of adult B-ALL and is associated with chemoresistance in those patients. In ph2, only 13% had ORR to single agent trastuzumab, with no CR. T-DM1 will probably have better efficacy if T doesn't promote cell death in ALL cells.
7:31 am Lpath: New published paper shows efficacy of Lpath's Anti-LPA Antibody, Lpathomab, in Traumatic Brain Injury models (LPTN) : As published by the Journal of Neuroinflammation (vol. 11, article 37), Lpathomab can be used to reduce the size of a TBI and to improve functional behavioral outcomes in experimental animal models. The antibody works as a molecular sponge by soaking up lysophosphatidic acid (:LPA), a molecule that can damage neurons and promote dangerous inflammatory responses in the central nervous system. In collaboration with scientists at the University of Melbourne, the antibody was tested in mice that had TBIs. A key finding of the study was the significant efficacy of administering Lpathomab after an injury, thus demonstrating a potential therapeutic benefit. Also shown for the first time in this groundbreaking paper was that human patients with TBI exhibited substantial increases in the levels of LPA in the cerebrospinal fluid (:CSF) after injury, a finding also seen in the injured mouse model of TBI; such data suggest that LPA is a valid target for therapeutic intervention......
Did I miss a PR from ACHN? Can't keep up anymore with my many biotechs. Can't even trade on events anymore.
I now remember why I have not been too excited about IMGN and SGEN's CD19 ADCs. Blinatumumab, the BITE that got acquired from Amgen has very high CRs, and none of the toxicity of the chemo part of ADCs. I was invested for awhile until buyout but now I can't even remember the name of the company. And before I finished typing that last sentence, my system was able to extract it from the deep recesses of my super cluttered brain: Micromet. MITI. The mighty mite.
Good luck to all.
Just like Bristol Myers is getting rid of their diabetes drugs to focus on oncology. And why Biogen got rid of their oncology pipeline to focus on neurology. Highly paid CEOs are expected to come up with "new and brilliant" ideas to increase their revenue and justify executive pay.
Hey, thanks for the heads up on ICPT. I bought 50 measly shares yesterday at 277 and flipped it at 464 this morning. It was a major OMG!. What a pleasant new year's gain! I should have bought 100 shares but I'm not a big gambler. After selling at 464, I thought of buying again when it dipped below 400 but was a little bit slow.
More upgrades to follow! Although sell on the news may happen first - I hope not.
I will have more in the money calls if pps surpasses $35!
Yeah, and they want to sell the company at $200 pps, not at $20. I want to sell at least $50 pps.
Then again, if the drugs are that promising, there is no way pps should be at $2. Heck, pps today should not even be at $4. This is being held down by the bright boys of Wall Street.
I have not loaded up on SGMO because I am waiting for the company to announce that they are stopping their HIV work to focus on other more promising monogenic disorders. I have regretted it because the price had since doubled. I wish they would announce the termination to get it out of the way, and give me confidence that they would not again pull the rug under investor's feet just like with their diabetic neuropathy drug. I am tired of sneaky biotech CEOs hiding long thought off plans from investors.
Short term, I'm hoping for a partnership so as to test ACHN's drugs in combo with the partner's other drugs. That's the only way ACHN and the other co can match or surpass GILD. That will give ACHN funds while awaiting for their other drugs to mature in the clinic.
Turns out I actually made close to 20k in 4 yrs trading in and out in this stock. Not too bad really.